Table 7.
Group | Post-challenge samples (no. positive/total) | |||||||
---|---|---|---|---|---|---|---|---|
Day 2 | Day 4 | Day6 | Day9 | |||||
Oa | Cb | O | C | O | C | O | C | |
Oil- TC/1 | 12/12c | 10/12 | 4/12 | 4/12 | 2/12 | 1/12 | 0 | 0 |
Oil-Las | 12/12 | 11/12 | 10/12 | 8/12 | 7/10 | 6/10 | 3/10 | 2/10 |
Live-Las | 12/12 | 10/12 | 9/12 | 8/12 | 5/10 | 4/10 | 2/9 | 2/9 |
Oil- TC/1plus Live-Las | 12/12 | 10/12 | 3/12* | 3/12* | 1/12 | 0 | 0 | 0 |
Oil-Las plus Live-Las | 12/12 | 11/12 | 8/12 | 7/12 | 5/12 | 3/12 | 2/11 | 1/11 |
Un-inoculated control | 12/12 | 12/12 | 12/12 | 12/12 | NSd | NS | NS | NS |
aOropharyngeal swabs. bCloacal swabs. cThe number in front of the slash represents the number of animals, which had detectable viral genome RNA; the number behind the slash stands for the total number of animals in this group. dNo survivors. *Significant difference (P < 0.05) among immunized groups with the column